Palatin Technologies, Inc. (NYSE: PTN) is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin’s programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. The company’s primary product in development is bremelanotide for the treatment of female sexual dysfunction. In addition, Palatin has development programs or drug candidates for erectile dysfunction, pulmonary diseases, heart failure, obesity, inflammatory diseases and dermatologic diseases. For more information, visit the company’s website at www.palatin.com